RT Journal Article
SR Electronic
T1 Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost
JF Heart
JO Heart
FD BMJ Publishing Group Ltd and British Cardiovascular Society
SP 175
OP 179
DO 10.1136/hrt.79.2.175
VO 79
IS 2
A1 Higenbottam, T W
A1 Butt, A Y
A1 Dinh-Xaun, A T
A1 Takao, M
A1 Cremona, G
A1 Akamine, S
YR 1998
UL http://heart.bmj.com/content/79/2/175.abstract
AB Objective To compare prostacyclin with an analogue, iloprost, in treatment of severe pulmonary hypertension.Patients Eight patients with severe pulmonary hypertension: primary in five, thromboembolic pulmonary hypertension in three.Methods All patients underwent right heart catheterisation. Mean (SEM) right atrial pressure was 9.9 (2.2) mm Hg, mean pulmonary artery pressure 67.4 (3.0) mm Hg, cardiac index 1.75 (0.13) l/min/m2 and mixed venous oxygen saturation 59.1(3.1)%. Continuous intravenous epoprostenol (prostacyclin, PGI2) or iloprost was given for phase I (three to six weeks); the patients were then crossed over to receive the alternate drug in an equivalent phase II.Main outcome measures Exercise tolerance was measured at baseline and at the end of phase I and II with a 12 minute walk; distance covered, rest period, percentage drop in arterial oxygen saturation (ΔSao 2%) and percentage rise in heart rate (ΔHR%).Results Walking distance covered rose from (mean (SEM)) 407.5 (73) to 591 (46) m with PGI2(p = 0.004) and to 602.5 (60) m while on iloprost (p = 0.008). Rest period decreased from 192 (73) seconds at baseline to 16 (16) seconds with PGI2 (p = 0.01) and to 58 (34) seconds with iloprost (p = 0.008). ΔHR% was 37.5(6)% at baseline, 35(3)% on PGI2, and 24(6)% on iloprost (p = 0.04).Conclusions Both intravenous PGI2 and iloprost caused significant improvement in exercise tolerance. Iloprost offers an alternative to PGI2 treatment of severe pulmonary hypertension.